A drug that belongs to the family of drugs called selective estrogen receptor modulators (SERMs) and is used in the prevention of osteoporosis in postmenopausal women. Raloxifene is also being studied as a cancer-prevention drug.
Information about Raloxifene
Raloxifene (ral ox' i feen) is a selective estrogen receptor modulator that has estrogen-like effects (agonism) on bone and the cardiovascular system but antiestrogen activity (antagonism) on breast and uterus tissue. This differential activity takes advantage of the beneficial effects of estrogens on bone in decreasing bone resorption and turnover and thus preventing osteoporosis, while avoiding the potential harmful effects of estrogen stimulation of breast and uterine tissue.
Mechanism of action of Raloxifene
In several large clinical trials, raloxifene was shown to increase bone mineral density and prevent bone fractures in postmenopausal women at high risk for osteoporosis, while decreasing serum cholesterol levels (both total and LDL) and without stimulating breast and uterine growth.
FDA approval information for Raloxifene
Raloxifene was approved for treatment and prevention of postmenopausal osteoporosis in the United States in 1997, and indications were expanded in 2007 to include reduction of risk of breast cancer in postmenopausal women with osteoporosis as well as those at high risk of breast cancer. Raloxifene is available in tablets of 60 mg generically and under the brand name Evista, and the recommended dose is 60 mg daily.
Side effects of Raloxifene
side effects are not common, but can include hot flashes, leg cramps, peripheral edema, arthralgias and sweating. Rare, but potentially severe adverse events include deep venous thrombosis, pulmonary embolism and ischemic strokes, side effects that it shares with estrogen.
Obstetrical and Gynecological Agents
Cost and Coupons - Raloxifene
- GoodRx compare cost & coupons for Raloxifene
- Find the lowest cost of Raloxifene
- Search for Coupons for Raloxifene
Reviews for Raloxifene
Learn more about Raloxifene
Latest research (Pubmed)